|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gauthier A and Ho M: Role of sorafenib in
the treatment of advanced hepatocellular carcinoma: An update.
Hepatol Res. 43:147–154. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Clevers H: The cancer stem cell: Premises,
promises and challenges. Nat Med. 17:313–319. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Oikawa T: Cancer stem cells and their
cellular origins in primary liver and biliary tract cancers.
Hepatology. 64:645–651. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ji J and Wang XW: Clinical implications of
cancer stem cell biology in hepatocellular carcinoma. Semin Oncol.
39:461–472. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Nishida N, Kitano M, Sakurai T and Kudo M:
Molecular mechanism and prediction of sorafenib chemoresistance in
human hepatocellular carcinoma. Dig Dis. 33:771–779. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Safe S, Nair V and Karki K:
Metformin-induced anticancer activities: Recent insights. Biol
Chem. 399:321–335. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Shi P, Liu W, Tala, Wang H, Li F, Zhang H,
Wu Y, Kong Y, Zhou Z, Wang C, et al: Metformin suppresses
triple-negative breast cancer stem cells by targeting KLF5 for
degradation. Cell Discov. 3:170102017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gritti M, Würth R, Angelini M, Barbieri F,
Peretti M, Pizzi E, Pattarozzi A, Carra E, Sirito R, Daga A, et al:
Metformin repositioning as antitumoral agent: selective
antiproliferative effects in human glioblastoma stem cells, via
inhibition of CLIC1-mediated ion current. Oncotarget.
5:11252–11268. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Nangia-Makker P, Yu Y, Vasudevan A,
Farhana L, Rajendra SG, Levi E and Majumdar AP: Metformin: A
potential therapeutic agent for recurrent colon cancer. PLoS One.
9:e843692014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chai X, Chu H, Yang X, Meng Y, Shi P and
Gou S: Metformin increases sensitivity of pancreatic cancer cells
to gemcitabine by reducing CD133+ cell populations and suppressing
ERK/P70S6K signaling. Sci Rep. 5:144042015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Mayer MJ, Klotz LH and Venkateswaran V:
Metformin and prostate cancer stem cells: A novel therapeutic
target. Prostate Cancer Prostatic Dis. 18:303–309. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shang D, Wu J, Guo L, Xu Y, Liu L and Lu
J: Metformin increases sensitivity of osteosarcoma stem cells to
cisplatin by inhibiting expression of PKM2. Int J Oncol.
50:1848–1856. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Siddappa G, Kulsum S, Ravindra DR, Kumar
VV, Raju N, Raghavan N, Sudheendra HV, Sharma A, Sunny SP, Jacob T,
et al: Curcumin and metformin-mediated chemoprevention of oral
cancer is associated with inhibition of cancer stem cells. Mol
Carcinog. 56:2446–2460. 2017. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Saito T, Chiba T, Yuki K, Zen Y, Oshima M,
Koide S, Motoyama T, Ogasawara S, Suzuki E, Ooka Y, et al:
Metformin, a diabetes drug, eliminates tumor-initiating
hepatocellular carcinoma cells. PLoS One. 8:e700102013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Liu F, Cao X, Liu Z, Guo H, Ren K, Quan M,
Zhou Y, Xiang H and Cao J: Casticin suppresses self-renewal and
invasion of lung cancer stem-like cells from A549 cells through
down-regulation of pAkt. Acta Biochim Biophys Sin (Shanghai).
46:15–21. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhao D, Zhai B, He C, Tan G, Jiang X, Pan
S, Dong X, Wei Z, Ma L, Qiao H, et al: Upregulation of HIF-2α
induced by sorafenib contributes to the resistance by activating
the TGF-α/EGFR pathway in hepatocellular carcinoma cells. Cell
Signal. 26:1030–1039. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
You A, Cao M, Guo Z, Zuo B, Gao J, Zhou H,
Li H, Cui Y, Fang F, Zhang W, et al: Metformin sensitizes sorafenib
to inhibit postoperative recurrence and metastasis of
hepatocellular carcinoma in orthotopic mouse models. J Hematol
Oncol. 9:202016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bae JS, Noh SJ, Kim KM, Jang KY, Chung MJ,
Kim DG and Moon WS: Serum response factor induces epithelial to
mesenchymal transition with resistance to sorafenib in
hepatocellular carcinoma. Int J Oncol. 44:129–136. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Mir N, Jayachandran A, Dhungel B, Shrestha
R and Steel JC: Epithelial-to-mesenchymal transition: A mediator of
sorafenib resistance in advanced hepatocellular carcinoma. Curr
Cancer Drug Targets. 17:698–706. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Dong J, Zhai B, Sun W, Hu F, Cheng H and
Xu J: Activation of phosphatidylinositol 3-kinase/AKT/snail
signaling pathway contributes to epithelial-mesenchymal
transition-induced multi-drug resistance to sorafenib in
hepatocellular carcinoma cells. PLoS One. 12:e01850882017.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chen HP, Shieh JJ, Chang CC, Chen TT, Lin
JT, Wu MS, Lin JH and Wu CY: Metformin decreases hepatocellular
carcinoma risk in a dose-dependent manner: Population-based and in
vitro studies. Gut. 62:606–615. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Guo Z, Cao M, You A, Gao J, Zhou H, Li H,
Cui Y, Fang F, Zhang W, Song T, et al: Metformin inhibits the
prometastatic effect of sorafenib in hepatocellular carcinoma by
upregulating the expression of TIP30. Cancer Sci. 107:507–513.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hirsch HA, Iliopoulos D, Tsichlis PN and
Struhl K: Metformin selectively targets cancer stem cells and acts
together with chemotherapy to block tumor growth and prolong
remission. Cancer Res. 69:7507–7511. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhang R, Zhang P, Wang H, Hou D, Li W,
Xiao G and Li C: Inhibitory effects of metformin at low
concentration on epithelial-mesenchymal transition of
CD44(+)CD117(+) ovarian cancer stem cells. Stem Cell Res Ther.
6:2622015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Gonzalez DM and Medici D: Signaling
mechanisms of the epithelial-mesenchymal transition. Sci Signal.
7(re8)2014.PubMed/NCBI
|
|
28
|
Ling S, Song L, Fan N, Feng T, Liu L, Yang
X, Wang M, Li Y, Tian Y, Zhao F, et al: Combination of metformin
and sorafenib suppresses proliferation and induces autophagy of
hepatocellular carcinoma via targeting the mTOR pathway. Int J
Oncol. 50:297–309. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chou CC, Lee KH, Lai IL, Wang D, Mo X,
Kulp SK, Shapiro CL and Chen CS: AMPK reverses the mesenchymal
phenotype of cancer cells by targeting the Akt-MDM2-Foxo3a
signaling axis. Cancer Res. 74:4783–4795. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lin H, Li N, He H, Ying Y, Sunkara S, Luo
L, Lv N, Huang D and Luo Z: AMPK inhibits the stimulatory effects
of TGF-β on Smad2/3 activity, cell migration, and
epithelial-to-mesenchymal transition. Mol Pharmacol. 88:1062–1071.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hsu CC, Wu LC, Hsia CY, Yin PH, Chi CW,
Yeh TS and Lee HC: Energy metabolism determines the sensitivity of
human hepatocellular carcinoma cells to mitochondrial inhibitors
and biguanide drugs. Oncol Rep. 34:1620–1628. 2015. View Article : Google Scholar : PubMed/NCBI
|
